Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
companyunderground
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Alzheimer's disease
Alzheimer's disease
Takeda wagers up to $2.2bn on AC Immune Alzheimer’s shot
Pharmaphorum
Mon, 05/13/24 - 11:13 am
Takeda
AC Immune
Alzheimer's disease
ACI-24.060
Acumen doses first patient in Phase II Alzheimer’s disease trial
Clinical Trials Arena
Thu, 05/9/24 - 07:16 pm
Acumen Pharmaceuticals
clinical trials
sabirnetug
Alzheimer's disease
Lilly gets a date with FDA to discuss Alzheimer's med donanemab
Fierce Biotech
Tue, 05/7/24 - 11:21 am
Eli Lilly
FDA
advisory committees
Alzheimer's disease
donanemab
Eli Lilly Gears Up for Donanemab Adcomm as FDA Ponders Changes to Format
BioSpace
Mon, 05/6/24 - 11:43 am
Eli Lilly
FDA
donanemab
advisory committees
Alzheimer's disease
Alzheimer's drug adoption in US slowed by doctors' skepticism
Reuters
Tue, 04/23/24 - 09:47 pm
Eisai
Biogen
Leqembi
physicians
Alzheimer's disease
Eisai hunts for next Alzheimer’s drug with new research pact
BioPharma Dive
Mon, 04/22/24 - 05:49 pm
Eisai
R&D
Alzheimer's disease
BioArctic
Roche’s Early Alzheimer’s Blood Test Gets FDA Breakthrough Device Designation
Xtalks
Thu, 04/18/24 - 10:28 pm
Roche
FDA
Medtech
Eli Lilly
Elecsys pTau217
Alzheimer's disease
diagnostics
Lilly Alzheimer's med glides out of Leqembi's slipstream with FDA adcomm request
Fierce Biotech
Wed, 04/17/24 - 09:58 pm
Eli Lilly
donanemab
Alzheimer's disease
Leqembi
Biogen
Eisai
FDA
FDA puts breakthrough tag on Roche, Lilly Alzheimer’s test
Pharmaphorum
Thu, 04/11/24 - 10:52 am
diagnostics
Roche
Eli Lilly
Alzheimer's disease
FDA
breakthrough designation
A dementia-focused VC digs past amyloid for new kinds of brain drugs
BioPharma Dive
Wed, 04/3/24 - 11:21 am
funding
venture capital
dementia
Dementia Discovery Fund
Alzheimer's disease
Psychosis: The Other Big Alzheimer’s Therapeutic Target
BioSpace
Tue, 04/2/24 - 11:46 am
Alzheimer's disease
Alzheimer's disease psychosis
Cerevel Therapeutics
Karuna Therapeutics
Biogen and Eisai Fall Behind on Leqembi’s Subcutaneous BLA for Alzheimer’s
BioSpace
Mon, 04/1/24 - 12:14 pm
Biogen
Eisai
Alzheimer's disease
Leqembi
Aduhelm and an expensive failure to launch
Pharmaphorum
Tue, 03/26/24 - 04:25 pm
Biogen
Alzheimer's disease
Aduhelm
drug launches
Eisai and Biogen facing delay to Leqembi in Europe
Pharmaphorum
Mon, 03/25/24 - 11:22 am
Eisai
Biogen
Leqembi
Europe
Alzheimer's disease
FDA guidelines consider amyloid reduction 'reasonably likely' to predict Alzheimer's benefit
Fierce Biotech
Tue, 03/12/24 - 11:34 am
Biogen
Eisai
Aduhelm
FDA
Alzheimer's disease
amyloid
Eli Lilly
donanemab
Roche Plots Neuro Comeback with Promising Mid-Stage Alzheimer’s Data
BioSpace
Tue, 03/12/24 - 11:14 am
Roche
Alzheimer's disease
monoclonal antibodies
Setbacks reset views on highly touted Alzheimer's and ALS drugs
Axios
Mon, 03/11/24 - 05:06 pm
Alzheimer's disease
ALS
Amylyx
Relyvrio
Eli Lilly
donanemab
Lilly’s Donanemab Hit with Surprise Delay, Set to Face FDA Adcomm
BioSpace
Fri, 03/8/24 - 11:55 am
Eli Lilly
FDA
Alzheimer's disease
donanemab
Tau, anti-inflammation and orals form Biogen's future Alzheimer's pipeline
Fierce Biotech
Thu, 03/7/24 - 11:38 am
Biogen
Alzheimer's disease
anti-tau antibodies
anti-inflammatory
Eisai
Leqembi
Japan's Eisai says US introduction of Alzheimer's drug Leqembi slower than expected
Reuters
Thu, 03/7/24 - 11:07 am
Eisai
Leqembi
drug launches
Alzheimer's disease
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »